؊1 and 13, respectively. The PI value of compound 4g was better than that of most marketed drugs. Structure-activity relationships are also described in this paper.
Epilepsy, one of the most common neurologic diseases, is characterized by epileptic seizures, which are evoked by unexpected, high-level neuronal discharges in the brain. 1) Since the anticonvulsant agents currently used in the treatment of epilepsy have certain disadvantages such as notable side effects and inefficient therapy in some seizure types, a clear need for safer and more effective antiepileptic drugs is well known. [1] [2] [3] Therefore the development of new antiepileptic drugs with approved therapeutic properties is an important challenge for medicinal chemists.
The derivatives of triazole exhibit a variety of activities such as antitumor, 4) antiinflammatory, 5) antimicrobial, 6, 7) antifugal, 8) antithrombotic, 9) antiplatelet, 10) antiviral, 11) and anticonvulsant activities. [12] [13] [14] In our search for new compounds with anticonvulsant activity, 6-benzyloxy-3,4-dihydro-1H-quinoline-2-one was found although its activity is low. To increase its anticonvulsant activity and taking into account the anticonvulsant activity of triazole, we incorporated triazole with 6-benzyloxy-3,4-dihydro-1H-quinolinone at the first and second position of the latter and obtained 7-benzyloxy-4,5-dihydro- [1, 2, 4] triazolo [4,3-a] quinoline with more potent activity. To search for better compounds and elucidate structure-activity relationships, a series of 1-substituted-7-benzyloxy-4,5-dihydro- [1, 2, 4] triazolo [4,3-a] quinolines was synthesized and their structures were characterized using IR, 1 H-NMR, MS, and elemental analysis techniques. The anticonvulsant activity was evaluated using the maximal eletroshock (MES) test and the subcutaneous pentylenetetrezole (sc-Met) test. Neurotoxicity was evaluated using the rotarod test.
CHEMISTRY
Melting points were determined in open capillary tubes and are uncorrected. IR spectra were recorded (in KBr ) on a FT-IR1730, 1 H-NMR spectra were measured on a BRUKER-300, and all chemical shifts are given in ppm relative to tetramethysilane. Mass spectra were measured on an AP12000 (EIS, 70 eV). Elemental analyses were performed on a Pekin-Elmer 204Q. Microanalyses of C, N, and H were performed using a Heraeus CHN Rapid Analyzer.
6-Hydroxy-3,4-dihydro-1H-quinoline-2-one 1 6-Hydroxy-3,4-dihydro-2-(1H)-quinoline-2-one was prepared from phenylamine and 3-chloro-propionylchloride using the method described previously, 15) the total yield was 59%, mp 234-236°C (value in the literature, 235-236°C).
6-Benzyloxy-3,4-dihydro-1H-quinoline-2-one 2 Sodium hydroxide (0.09 mol), 60 ml of absolute ethanol, and 6-hydroxy-3,4-dihydro-(1H)-quinoline-2-one (0.03 mol) were added to a 100 ml round-bottomed flask equipped with a reflux condenser, and chloromethyl-benzene (0.36 mol) was added dropwise to the mixture. The reaction mixture was refluxed for 2.5 h and cooled. After being poured into 100 ml of ice-water, a white solid was obtained through filtration, which was dried in a vacuum and recrystallized in hexane-ethannol 6-Benzyloxy-3,4-dihydro-1H-quinoline-2-thione 3 Some improvements were made based on the method described previously. 16) Acelonitrile 30 ml and triethylamine 20 ml were placed in a three-necked round-bottomed flask, to which P 2 S 5 1.3 g was added slowly in an ice bath and stirred until dissolved. Then 2 was added with stirring. The mixture was refluxed for 3 h in a nitrogen atmosphere. After removing the solvent under reduced pressure, the residue was dissolved in 30 ml of dichloromethane, washed with water (30ϫ3), and dried over anhydrous MgSO 4 . Evaporation of the solvents gave a crude product that was purified by recrystallization in hexane-ethanol a]quinolines 4a-n The method described previously was used with some improvements. Compound 3, suitable acylhydrazine, and cyclohexanol 60 ml were added to a 100 ml three-necked round-bottomed flask, and the mixture was refluxed for 6 h in a nitrogen atmosphere. Solvents were removed under reduced pressure, and the residue was extracted twice with dichloromethane 30 ml. The dichloromethane layer was washed three times with water (30ϫ3) and dried over anhydrous MgSO 4 . After removing the solvents, products was purified by silica gel column chromatography (dichloromethane : methanolϭ10 : 1).
7 17, 18) All compounds were tested for anticonvulsant activity with C57B/6 mice in the 18-25 g weight range purchased from the Laboratory of Animal Research, College of Pharmacy, Yanbian University. The tested compounds were dissolved in polyethylene glycol-400.
In Phase I screeng (Table 1) each compound was administered at three dose levels (30, 100, and 300 mg/kg i.p., to a total of 6 mice, using 2 for each dose) with anticonvulsant activity and neurotoxicity assessed at 30-min and 4-h intervals after administration. Anticonvulsant efficacy was measured in the MES test and the scMet test. In the MES test, seizures were elicited with a 60 Hz alternating current of 50 mA intensity in mice. The current was applied via corneal electrodes for 0.2 s. Abolition of the hind-leg tonic-extensor component of the seizure indicated protection against the spread of MES-induced seizures. The scMet test involved subcutaneous injection of a convulsant dose (CD 97 ) of pentylenetetrazol (85 mg/kg in mice). Elevation of the pentylenetrazol-induced seizure threshold was indicated by the absence of clonic spasms for at least 5-s duration over a 30-min period following administration of the test compound. Anticonvulsant drug-induced neurologic deficit was detected in mice using the rotorod ataxia test. The pharmacologic parameters estimated in phase I screening were quantified for compounds 4a-c, 4e, 4g-i, and 4l in phase II screening (Table 2) . Anticonvulsant activity was expressed in terms of the median effective dose (ED 50 ), and neurotoxicity was expressed as the median toxic dose (TD 50 ). For determination of the ED 50 and TD 50 values, groups of 10 mice were given a range of intraperitoneal doses of the test drug until at least three points were established in the range of 10-90% seizure protection or minimal observed neurotoxicity. From the plot of this data, the respective ED 50 and TD 50 values, 95% confidence intervals, slope of the regression line, and the standard error of the slope were calculated by means of a computer program written at National Institue of Neurological Disorders and Stroke.
RESULTS AND DISCUSSION
Based on previous reports, [12] [13] [14] we knew that trazoles have activity against both major and minor seizures. The MES test is regarded as the pharmacologic model of grand mal, and the sc-Met test as the pharmacologic model of petit mal seizures. Therefore we carried out those two tests to 1218 Vol. 28, No. 7 evaluate the anticonvulsant activity of the synthesized compounds.
The compounds were tested for anticonvulsant activity using the procedures described previously. 17, 18) The initial evaluation (phase I) of anticonvulsant activity of synthesized compounds is presented in Table 1 . The compounds were administered intraperitoneally at three doses (30, 100, 300 mg · kg
Ϫ1
). Three tests were performed for each compound: MES-induced convulsions, sc-Met-induced convulsions, and rotarod neurotoxicity test.
As a result of preliminary screening , compounds 4a-c, 4e, 4g-i, and 4l were subjected to phase II trials for quantification of their anticonvulsant activity and neurotoxicity in mice. This phase provides an evaluation of the ED 50 and TD 50 values. The 95% confidence interval, slope of the regression line, and SE of the slope were then calculated. These data are shown in Table 2 , which also includes comparisons with marketed antiepileptic drugs such as phenytoion, carbamazepine, phenobarbital, and valproate. Some of these derivatives showed a high degree of protection against MES-induced seizures, although they were less effective against scMet-induced seizures.
The following structure-activity relationships were observed. In a series of alkyl substitutions at the first position, the increase in the carbon number at the first position decreased the anticonvulsant activity markedly. The ED 50 values of compounds 4a-c, which were H, CH 3 ). Among the aryl-substituted derivatives at the first position, the potency of compounds containing a substituted phenyl at the first position was less than that of those with an unsubstituted phenyl. Compounds 4g, 4h, and 4j, which were -Ph, 3-CH 3 Ph, or 3-OCH 3 Ph at the first position, respectively, had corresponding ED 50 value in the MES test of 23, 30.4, and 60.6 mg · kg
, respectively. Introduction of a chlorine atom into the phenyl at the first position of the derivatives lead to a complete loss of potency, as seen in compounds 4f, 4j, 4k, and 4n, which did not exhibit any anticonvulsant activity in the MES test even at a dose of 300 mg · kg
. Compounds substituted with a pyridine at the first position exhibited less activity than those substituted with a phenyl. Compound 4l, which was substituted with pyridine at the first position, with an ED 50 value of 58.5 mg · kg Ϫ1 in the MES test, was less active than compound 4g (ED 50 ϭ23.0 mg · kg
) which was substituted with a phenyl at the first position.
The neurotoxicity of compounds with an unsubstituted phenyl was less than that of those with a substituted phenyl. Therefore compound 4g with a TD 50 value of greater than 300 mg · kg
, ED 50 of 23.0 mg · kg Ϫ1 , and protective index (PIϭTD 50 /ED 50 ) of more than 13 was the safest among the compounds synthesized. Compared with the marketed drugs, its ED 50 value was comparable to that of phenobarbital in the MES test but its PI value was higher than that of phenytoin, carbamazepine, phenobarbital, and valproate. No dose-resistance tendency was seen. With the increase in dose, activity against both types of seizure improved, although their toxicity also became greater. 19) e) 95% confidence limits.
